Demannose

Demannose

SCHEMBL461962

O=C[C@H](O)[C@@H](O)[C@H](O)CO.O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
TDP1 Q9NUW8 1/20 0.52
PDE4A P27815 1/20 0.44
AKR1B1 P15121 1/20 0.42
USP2 O75604 1/20 0.41
SLCO1B1 Q9Y6L6 1/20 0.41
KDM4E B2RXH2 2/20 0.39
MPI P34949 1/20 0.34
CYP2C19 P33261 1/20 0.32
HIF1A Q16665 1/20 0.32
TOP1 P11387 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Demannose SCHEMBL3904983 1.00 LMNA (0.55) LMNAL3MBTL1TDP1PDE4AAKR1B1
Demannose SCHEMBL6750831 1.00 LMNA (0.55) LMNAL3MBTL1TDP1PDE4AAKR1B1
Galactose SCHEMBL14856251 1.00 LMNA (0.55) LMNAL3MBTL1TDP1PDE4AAKR1B1
Demannose SCHEMBL8528284 1.00 LMNA (0.55) LMNAL3MBTL1TDP1PDE4AAKR1B1
Galactose SCHEMBL1548813 1.00 LMNA (0.55) LMNAL3MBTL1TDP1PDE4AAKR1B1
Demannose SCHEMBL22712624 1.00 LMNA (0.55) LMNAL3MBTL1TDP1PDE4AAKR1B1
Demannose SCHEMBL6055085 1.00 LMNA (0.55) LMNAL3MBTL1TDP1PDE4AAKR1B1
Demannose SCHEMBL2799182 1.00 LMNA (0.55) LMNAL3MBTL1TDP1PDE4AAKR1B1
Demannose SCHEMBL20817166 1.00 LMNA (0.55) LMNAL3MBTL1TDP1PDE4AAKR1B1
Demannose SCHEMBL1858493 1.00 LMNA (0.55) LMNAL3MBTL1TDP1PDE4AAKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 364 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250288601-A1 METHODS FOR TREATING UROGENITAL HEALTH CONDITIONS ONE BIO INC (US) 2025-09-18 US claimed
EP-4522124-A2 METHODS FOR TREATING UROGENITAL HEALTH CONDITIONS One Bio Inc (US) 2025-03-19 EP claimed
WO-2023220318-A2 METHODS FOR TREATING UROGENITAL HEALTH CONDITIONS BCD BIOSCIENCE, INC. (US) 2023-11-16 WO claimed
CN-116445305-A Marine fungus for producing squalene by utilizing xylose and application thereof 中国科学院青岛生物能源与过程研究所 2023-07-18 CN claimed
CN-109744362-B Mixed feed additive for tilapia 浙江海洋大学 2022-03-29 CN claimed
CN-113475630-A Method for preparing flavoring agent for cats by using Maillard reaction intermediate 江苏翼邦生物技术有限公司 2021-10-08 CN claimed
CN-105815176-B A kind of production method of selenium-enriched health care tealeaves 云南欣确生物科技有限公司 2019-03-05 CN claimed
CN-109239160-A A kind of glucose sensor of Novel free xylose interference 江苏鱼跃医疗设备股份有限公司 2019-01-18 CN claimed
CN-108740818-A A kind of preparation method of fermentation duck leg 宁波大学 2018-11-06 CN claimed
CN-104982972-B A kind of method of the bioanalysis control excessive lipid oxidation of cured fish process 中国水产科学研究院南海水产研究所 2018-08-21 CN claimed
CN-103948530-B A kind of precious Rogor moisture-keeping composition and preparation method thereof 广州雅纯化妆品制造有限公司 2016-06-15 CN claimed
US-20150344532-A1 ENGINEERED XYLOSE TRANSPORTERS WITH REDUCED GLUCOSE INHIBITION BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2015-12-03 US claimed
WO-2015179701-A1 ENGINEERED XYLOSE TRANSPORTERS WITH REDUCED GLUCOSE INHIBITION BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2015-11-26 WO claimed
CN-104982972-A Method for controlling excessive lipid oxidation in fish salting and drying processes through biological method SOUTH CHINA SEA FISHERIES RES 2015-10-21 CN claimed
CN-104721301-A Apple polyphenol ethanol extract as well as preparation method and application thereof MEDICAL COLLEGE CAPF 2015-06-24 CN claimed
CN-103269673-A Fluid composition comprising a structuring agent COLGATE PALMOLIVE CO 2013-08-28 CN claimed
CN-101255446-B Method for continuous fermentation of glucose xylose by coupling immobilized yeast cell and pervaporation membrane UNIV DALIAN TECH 2010-09-29 CN claimed
CN-101255446-A Method for continuous fermentation of glucose xylose by coupling immobilized yeast cell and pervaporation membrane UNIV DALIAN TECH (CN) 2008-09-03 CN claimed
CN-1205907-C Cosmetic composition containing polysaccharide and tripolymer of acrylic acid and its use for protecting cuticles OREAL (FR) 2005-06-15 CN claimed
CN-1243698-A Cosmetic composition containing polysaccharide and tripolymer of acrylic acid and its use for protecting cuticles OREAL (FR) 2000-02-09 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150344532-A1 ENGINEERED XYLOSE TRANSPORTERS WITH REDUCED GLUCOSE INHIBITION SLC2A1, SLC2A8, SLC2A4 LMNA 4684/4885L3MBTL1 1329/4885TDP1 1550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.